Artivion Yönetim

Yönetim kriter kontrolleri 3/4

Artivion CEO'su Pat Mackin, Sep2014 tarihinde atandı, in görev süresi 10.17 yıldır. in toplam yıllık tazminatı $ 3.18M olup, şirket hissesi ve opsiyonları dahil olmak üzere 24.4% maaş ve 75.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.59% ine doğrudan sahiptir ve bu hisseler € 18.06M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.3 yıl ve 8.1 yıldır.

Anahtar bilgiler

Pat Mackin

İcra Kurulu Başkanı

US$3.2m

Toplam tazminat

CEO maaş yüzdesi	24.4%
CEO görev süresi	10.2yrs
CEO sahipliği	1.6%
Yönetim ortalama görev süresi	4.3yrs
Yönetim Kurulu ortalama görev süresi	8.1yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Pat Mackin'un ücretlendirmesi Artivion'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$842k
Jun 30 2024	n/a	n/a	-US$8m
Mar 31 2024	n/a	n/a	-US$10m
Dec 31 2023	US$3m	US$776k	-US$31m
Sep 30 2023	n/a	n/a	-US$24m
Jun 30 2023	n/a	n/a	-US$28m
Mar 31 2023	n/a	n/a	-US$29m
Dec 31 2022	US$7m	US$750k	-US$19m
Sep 30 2022	n/a	n/a	-US$41m
Jun 30 2022	n/a	n/a	-US$17m
Mar 31 2022	n/a	n/a	-US$15m
Dec 31 2021	US$5m	US$728k	-US$15m
Sep 30 2021	n/a	n/a	US$2m
Jun 30 2021	n/a	n/a	-US$12m
Mar 31 2021	n/a	n/a	-US$13m
Dec 31 2020	US$3m	US$606k	-US$17m
Sep 30 2020	n/a	n/a	-US$14m
Jun 30 2020	n/a	n/a	-US$11m
Mar 31 2020	n/a	n/a	-US$5m
Dec 31 2019	US$6m	US$689k	US$2m
Sep 30 2019	n/a	n/a	US$2m
Jun 30 2019	n/a	n/a	US$3m
Mar 31 2019	n/a	n/a	US$709k
Dec 31 2018	US$3m	US$660k	-US$3m
Sep 30 2018	n/a	n/a	-US$5m
Jun 30 2018	n/a	n/a	-US$5m
Mar 31 2018	n/a	n/a	-US$2m
Dec 31 2017	US$3m	US$640k	US$4m

Tazminat ve Piyasa: Pat 'nin toplam tazminatı ($USD 3.18M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.46M ).

Tazminat ve Kazançlar: Pat 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Pat Mackin (57 yo)

10.2yrs

Görev süresi

US$3,176,413

Tazminat

Mr. James Patrick Mackin, also known as Pat, has been the Chief Executive Officer and President of Artivion, Inc. (formerly known as CryoLife, Inc.) since September 02, 2014 and has been its Chairman since...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
James Mackin	Chairman	10.2yrs	US$3.18m	1.59% € 18.1m
Lance Berry	Executive VP of Finance	less than a year	US$1.64m	0.19% € 2.1m
Amy Horton	VP & Chief Accounting Officer	18.3yrs	US$1.06m	0.33% € 3.8m
Jean Holloway	Senior VP	9.6yrs	US$993.72k	0.39% € 4.4m
John Davis	Senior VP & Chief Commercial Officer	less than a year	US$953.41k	0.38% € 4.3m
Matthew Getz	VP of Human Resources & Chief Human Resources Officer	5.3yrs	Veri yok	0.081% € 925.1k
Marshall Stanton	Senior VP of Clinical Research & Chief Medical Officer	3.7yrs	US$1.61m	0.20% € 2.3m
Robert Thomson	Vice President of Research & Development	1.4yrs	Veri yok	0.032% € 360.5k
Florian Tyrs	Vice President of Global Operations	4.3yrs	Veri yok	0.061% € 696.6k

4.3yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim: CYL 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
James Mackin	Chairman	10.1yrs	US$3.18m	1.59% € 18.1m
James Bullock	Independent Director	8.1yrs	US$217.50k	0.15% € 1.7m
Thomas Ackerman	Independent Director	20.9yrs	US$230.00k	0.34% € 3.9m
Anthony Semedo	Independent Director	3.1yrs	US$217.50k	0.081% € 926.3k
Daniel Bevevino	Independent Director	20.9yrs	US$235.00k	0.34% € 3.9m
Jeffrey Burbank	Independent Presiding Director	7.2yrs	US$265.00k	0.11% € 1.3m
Jon Salveson	Independent Director	12.5yrs	US$215.00k	0.29% € 3.3m
Marna Borgstrom	Independent Director	6.4yrs	US$220.00k	0.10% € 1.2m
Elizabeth Hoff	Independent Director	2.1yrs	US$210.00k	0.060% € 679.7k

8.1yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CYL 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.1 yıldır).

Artivion Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Insufficient new directors

Independent Director recently sold €221k worth of stock

Artivion, Inc., Annual General Meeting, May 14, 2024

Chairman recently sold €241k worth of stock

Chairman recently sold €224k worth of stock

Artivion, Inc. Announces Chief Financial Officer Changes

Recent updates

Now 20% undervalued

Artivion, Inc. Lowers Earnings Guidance for the Full Year 2024

Artivion, Inc. Lowers Earnings Guidance for the Full Year 2024

Third quarter 2024 earnings released: US$0.055 loss per share (vs US$0.24 loss in 3Q 2023)

Insufficient new directors

Artivion, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Independent Director recently sold €221k worth of stock

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: US$0.051 loss per share (vs US$0.083 loss in 2Q 2023)

Artivion, Inc. Revises Earnings Guidance for the Year 2024

Artivion, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Artivion, Inc. Revises Earnings Guidance for the Year 2024

First quarter 2024 earnings released: EPS: US$0.18 (vs US$0.33 loss in 1Q 2023)

Artivion, Inc. to Report Q1, 2024 Results on May 06, 2024

Artivion, Inc., Annual General Meeting, May 14, 2024

New minor risk - Shareholder dilution

Chairman recently sold €241k worth of stock

Full year 2023 earnings released: US$0.75 loss per share (vs US$0.48 loss in FY 2022)

Chairman recently sold €224k worth of stock

Artivion, Inc. Provides Earnings Guidance for the Year 2024

Full year 2023 earnings released: US$0.75 loss per share (vs US$0.48 loss in FY 2022)

Artivion, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Artivion, Inc. announced that it expects to receive $350 million in funding

Artivion, Inc. Announces Chief Financial Officer Changes

Artivion, Inc. Announces Completion of Enrollment in PERSEVERE Trial

Artivion, Inc. Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.34 loss in 3Q 2022)

Artivion, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New minor risk - Share price stability

Artivion, Inc. Announces Data from On-X Aortic Heart Valve Low INR Post-Market Study Presented in A Late-Breaking Science Session At the 37European Association for Cardio-Thoracic Surgery Annual Meeting

Artivion, Inc. Revises Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: US$0.083 loss per share (vs US$0.11 loss in 2Q 2022)

Artivion, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Senior Vice President of Operations recently sold €232k worth of stock

Artivion Revises Earnings Guidance for the Year 2023

First quarter 2023 earnings released: US$0.34 loss per share (vs US$0.085 loss in 1Q 2022)

Chairman recently sold €276k worth of stock

Artivion, Inc. Provides Earnings Outlook for the Year 2023

Full year 2022 earnings released: US$0.48 loss per share (vs US$0.38 loss in FY 2021)

Artivion, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Third quarter 2022 earnings released: US$0.34 loss per share (vs US$0.27 profit in 3Q 2021)

Artivion, Inc. Provides Earnings Guidance for the Fourth Quarter of 2022

Artivion, Inc. Provides Revenue Guidance for the Year 2022

Artivion, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Artivion, Inc. Announces the Appointment of Elizabeth A. Hoff to Board of Directors

Artivion Follows Recommendation to Stop PROACT Xa Clinical Trial

Insider recently sold €122k worth of stock

Second quarter 2022 earnings released: US$0.11 loss per share (vs US$0.056 loss in 2Q 2021)

Artivion, Inc. Provides Financial Guidance for the Year 2022

Artivion Initiates Enrollment in PERSEVERE Clinical Trial

Artivion, Inc. to Report Q2, 2022 Results on Aug 04, 2022

First quarter 2022 earnings released: US$0.085 loss per share (vs US$0.08 loss in 1Q 2021)

Artivion, Inc. Provides Revenue Guidance for the Year 2022

Insufficient new directors

Artivion, Inc. to Report Q1, 2022 Results on May 05, 2022

Artivion, Inc., Annual General Meeting, May 18, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Artivion Provides Revenue Guidance for the Full Year 2022

Artivion, Inc. to Report Q4, 2021 Results on Feb 17, 2022

Artivion, Inc. Announces Publication of On-X® Mitral Heart Valve PROACT Study Results in the Annals of Thoracic Surgery

Insufficient new directors

Director recently bought €231k worth of stock

Third quarter 2021 earnings released: EPS US$0.27 (vs US$0.075 loss in 3Q 2020)

Insider recently sold €59k worth of stock

Insufficient new directors

Second quarter 2021 earnings released: US$0.056 loss per share (vs US$0.098 loss in 2Q 2020)

Insufficient new directors

CryoLife, Inc.(NYSE:CRY) dropped from Russell 2000 Value-Defensive Index

CryoLife, Inc.(NYSE:CRY) dropped from Russell 2000 Defensive Index